If your binder discovery campaign is between phage and yeast display, the choice usually comes down to library size, post-translational modifications, and how you plan to read out affinity. There is no universal “best” platform. Choosing wrong wastes a quarter; choosing right compounds. This is how we decide.
The three platforms in one paragraph each
Phage display uses M13 or T7 phage to present scFv, Fab, or peptide libraries on the phage coat. Library sizes routinely reach 10^11 to 10^12 unique variants. Selection happens through panning rounds against immobilized antigen. The displayed protein is folded in the bacterial periplasm, which limits post-translational modifications to bacterial chaperone-assisted folding. Phage displays at 1-5 copies per particle, so avidity effects are present but tractable.
Yeast surface display services anchor proteins to the yeast cell wall via the Aga2p mating protein or similar fusions. Library sizes are 10^7 to 10^9 unique variants, set by transformation efficiency. Display levels of 10,000-100,000 copies per cell create strong avidity, which is both an advantage (rare binders pull out) and a liability (apparent affinity can be inflated 100-1000x; see the avidity artifacts article). Selection uses FACS or MACS, and quantitative readout via flow cytometry is the standout feature.
Mammalian cell display (CHO or HEK293) presents proteins through transmembrane fusion or PDGFRβ-anchored constructs. Library sizes are 10^6 to 10^8 — smaller than yeast — but the cells handle full glycosylation, complex disulfide networks, and the secretory pathway machinery that yeast and bacteria cannot replicate. Used when target binding depends on PTMs the other platforms cannot install.
The decision framework
| Dimension | Phage | Yeast | Mammalian |
|---|---|---|---|
| Library size ceiling | 10^11-10^12 | 10^7-10^9 | 10^6-10^8 |
| PTM fidelity (glycosylation, disulfides) | Limited | Moderate (yeast-style high-mannose) | Native human |
| Quantitative affinity readout | Indirect (ELISA after panning) | Direct (flow cytometry) | Direct (flow cytometry) |
| Avidity inflation | Low (1-5 copies/particle) | High (10K-100K copies/cell) | Moderate (titratable) |
| Throughput per round | High (10^11 input) | Moderate (10^9 input) | Lower (10^7 input) |
| Cost per campaign | Lowest | Mid | Highest |
| Time per round | 1-3 days | 3-5 days | 5-7 days |
| Suitable for full-length IgG | No | No (Fab/scFv only practical) | Yes |
When to use which
Choose phage display when:
- You need to interrogate a sequence space larger than 10^9. The library size advantage is real and not replaceable.
- Your scaffold is small (peptides, scFv, single-domain antibodies) and doesn’t require complex PTMs.
- You’re at the discovery stage and willing to triage false positives in subsequent rounds.
- Cost is the primary constraint. Phage panning is the cheapest of the three to run.
Choose yeast display when:
- You need quantitative affinity ranking from the screen itself (flow cytometry gives a Kd estimate per clone in one experiment).
- Your library fits in 10^9 — usually true for focused or AI-designed libraries.
- You need to characterize multiple binders simultaneously rather than just enrich for the strongest. The avidity-corrected, single-clone Kd readout is a serious advantage when ranking multiple leads.
- You plan to do directed evolution rounds — the titratable display level lets you tune selection stringency precisely.
Choose mammalian display when:
- The target requires native glycosylation, complex disulfide networks, or PTM-dependent epitopes (Fc-mediated effector function, Fc-FcRn binding, glycan-specific antibodies).
- You’re optimizing a full-length IgG, where yeast display’s truncation to scFv/Fab loses developability information.
- You’re past the discovery stage and need developability triage under conditions that match production cells.
Edge cases — when you actually need more than one
Most of our flagship campaigns use two platforms sequentially, not one. The most common pattern: yeast display for affinity discovery, mammalian display for developability validation. The yeast round generates and enriches binders fast; the mammalian round filters out variants that fail PTM compatibility before commitment to expression scale-up. We’ve documented this pattern at length in the two-platform approach article.
A second pattern: phage display for the initial diversity sweep (10^11 library), followed by yeast display for the quantitative rank-order on the top 10^4-10^5 hits. This works well when the target is hard and a focused library would miss the right epitope.
A third pattern, less common: mammalian display from round one when the target itself is a glycoprotein and yeast-displayed binders consistently fail to recapture the relevant epitope. Membrane-bound complement proteins are a typical example.
How AI design changes the calculus
When the input library is AI-designed rather than randomly diversified, the library-size advantage of phage display matters less. Ranomics’ AI design pipeline typically produces 10,000 to 60,000 candidate binders per campaign — well within yeast display’s working range. In this regime, the quantitative affinity readout becomes the dominant criterion, which favors yeast or mammalian display over phage.
The integrated picture: AI design narrows the search space, display screening validates and ranks. Phage display’s “search” advantage is replaced by computational sampling. Yeast display’s “rank” advantage remains essential.
Decision summary
If you’re between phage and yeast and you have an AI-designed library: choose yeast.
If you have a randomly diversified library that needs to be larger than 10^9: choose phage, with a yeast follow-up.
If your target’s biology depends on PTMs: skip both and go to mammalian display.
If you’re not sure: get into a 30-minute conversation about your target structure, library design, and downstream validation plan. The right platform is downstream of those choices, not upstream.
Ranomics designs and screens binders on all three platforms. If you’re scoping a campaign and want a second opinion on platform fit, start a Binder Pilot or reach out via the contact page.